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Chronic Idiopathic Thrombocytopenic Purpura 
Effective preoperative preparation and long-term results of splenectomy 
James C . Gruenberg, MD,* Melvin A. Block, MD,** Ellis J. Van Slyck, MD,*** 
and Joseph P. AbraJiam, MD*** 
A retrospective review of 98 patients seen at Henry Ford 
Hospital from 1953 through 1977 demonstrated that 
splenectomy for chronic idiopathic thrombocytopenic 
purpura provided a good response which usually was 
sustained on long-term follow-up (72% at 15 years). 
Although splenectomy for this condition had a low mor-
tality, morbidity was significant in patients older than 40 
years. 
When compared to patients whose response to splenec-
tomy was sustained, patients who relapsed had signifi-
cantly lower platelet counts preoperatively both when 
they were untreated (mean: 9,194 per cc versus 18,524 
per-cc) and/or when they were treated with steroids 
(mean: 85,647 per cc versus 142,590 per cc). Another 
significant risk factor for relapse was a longer interval 
from splenectomy to the maximum postoperative plate-
let count. 
In the immediate preoperative preparation ofthe patient 
for splenectomy, corticosteroids temporarily increased 
the platelet count, but high doses were necessary in 
many patients. A platelet count of greater than 40,000/cc 
usually was achieved with a dose of 60 to 80 mgs of 
prednisone per day for several days. Platelet infusion 
rarely was needed if patients were prepared adequately 
with steroids. There should be no hesitation to give large 
doses of steroids for a few days, and a delay in proceed-
ing with the operation, once indicated, should be 
avoided. Because the response ofthe platelet count to 
splenectomy may be variable or fluctuating and late 
relapses can occur, patients should be re-evaluated 
periodically. 
Splenectomy is often performed for the treatment of 
chronic idiopathic thrombocytopenic purpura (ITP). 
The operation is considered safe, and bleeding compl i -
cations are minimized if preoperative blood platelet 
counts are higher than 40,000/cc, because circulating 
platelets in this condi t ion are young and functionally 
sound (1). Our study of experience with this disorder at 
Henry Ford Hospital was designed to determine the 
dependabil ity of short-term glucocort icoid (steroid) 
administration in providing adequate preoperative plate-
let levels and to determine the long-term effectiveness 
of splenectomy. 
Clinical Materials 
We reviewed the medical records of all patients who had 
been diagnosed for thrombocytopenia at Henry Ford 
Hospital between 1953 and 1977, and we selected 98 
patients for study. Excluded were patients whose throm-
bocytopenia had a recognized etiology; patients, par-
ticularly chi ldren, whose idiopathic disease was acute; 
patients with systemic lupus erythematosus; and patients 
who had undergone splenectomy at another hospital. 
Reports of bone marrow examination were reviewed for 
all patients in order to verify findings typical for ITP. 
In order to determine postoperative morbidity, platelet 
response before and after splenectomy, and the nature 
of relapse after splenectomy, we examined 11 variables: 
age, sex, duration of symptoms, duration of known 
thrombocytopenia, lowest preoperative platelet count, 
highest preoperative platelet count, clinical response to 
steroid therapy, spleen weight, maximum postoperative 
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platelet count, the day of maximum platelet count, and 
major postoperative complications. All patients were 
fo l lowed f rom one month to34 years, wi th a mean of 4.3 
years. Their distr ibut ion by age and sex is shown in 
Figure 1. 
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Ages of patients at t ime of splenectomy. 
In general, our approach to the patient suspected of 
having chronic ITP was to initiate a trial of steroid ther-
apy while appropriate tests were carried out to conf i rm 
the diagnosis. Steroid medication was cont inued until 
the patient became asymptomatic and the platelet count 
exceeded 100,000/cc. The steroid dosage was then 
reduced gradually over several weeks, and the patient's 
platelet count was again measured. 
On the basis of their preoperative response to steroid 
therapy, five groups of patients were identif ied: 
1) 7 patients became asymptomatic and maintained 
platelet counts greater than 100,000/cc for varying 
periods after steroids had been discontinued. 
2) 26 patients had platelet counts in excess of 100,000/cc 
but could not maintain this level wi thout low doses 
of steroid medication. 
3) 42 patients fai led to reach platelet counts of 
100,000/cc on high or moderate doses of steroids 
(greater than 20 mg of prednisone per day) or sus-
tained a steroid complicat ion, e.g., compression 
fracture or Cushingoid habitus. 
4) 8 patients did not receive steroid therapy or had 
splenectomy before a trial of steroid therapy could 
be completed. For this reason, we were unable to 
evaluate this group of patients. 
5) 15 patients did not achieve a platelet count of 
40,000/cc. Within this group, nine patients received 
less than 60 mg of prednisone per day, four 
received 60-80 mg of prednisone per day, and two 
patients received more than 120 mg of prednisone 
per day. 
If thrombocytopenia persisted or the patient could not 
be removed f rom steroid medication completely w i th-
out a significant drop in the platelet count, splenectomy 
was considered. Becauseof thewel l -known risksof con-
tinuous long-term steroid administration, we preferred 
to proceed with splenectomy with in three months o f the 
onset of known thrombocytopenia when it became 
apparent that the patient could not safely be withdrawn 
from steroid therapy. 
Results 
Clinical response after splenectomy 
We considered the clinical response after splenectomy 
to be good if the patient was asymptomatic, maintained 
normal platelet counts, and required no steroid therapy. 
As displayed by the life table method (Fig. 2), the 
response of our 98 patients to splenectomy was good 
and sustained to a remarkable degree (72% at 15 years). 
Nineteen of 98 patients relapsed after splenectomy, and 
their response fell into one of three clinical groups. One 
group consisted o f ten patients who experienced throm-
bocytopenia after splenectomy and required cont inu-
ous steroid therapy postoperatively. Eight of the ten 
relapsed with in one year after surgery, the other two at 
three and 15 years postoperatively. A second group of 
three patients had platelet counts that fluctuated between 
normal and thrombocytopenic. They required steroid 
medication intermittently and relapsed within six months 
after splenectomy. In the th i rd group were six patients 
who had normal postoperative platelet counts but occa-
sionally required steroid medication for brief episodes 
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Cumulat ive patient survival w i thou t relapse after splenectomy. 
of thrombocytopenia. Two of these six relapsed with in 
one year after splenectomy, the other four at two, three, 
seven, and 18 years postoperatively. 
Platelet response after splenectomy 
Before splenectomy, a series of platelet counts was taken 
for each patient in the study, which ranged f rom a min-
imum of three to as many as 40 in a few cases. The rise in 
the platelet count was plotted for each patient, and 
these elevations were then compared among patients. 
Each patient's lowest preoperative platelet count, usu-
ally obtained at the t ime of initial presentation, was 
higher (mean: 18,524/cc) in patients whose response to 
splenectomy was sustained than in those patients who 
relapsed (mean: 9,194/cc) (P=0.0246), although the sta-
tistical variance was large in each group. Similarly, each 
patient's highest preoperative platelet count, usually 
obtained when the patient was receiving steroid medi-
cation, was higher in those patients who did not relapse 
after splenectomy (mean: 142,590/cc) than in those who 
did (mean: 85,647/cc) (P=0.0284). This difference was 
more significant at lower platelet counts (P=0.0162 at 
40,000/cc versus P=0.0527 at 100,000/cc), indicating that 
the risk of relapse was greatest for patients who had the 
poorest response to steroid therapy as measured by 
platelet counts. Thus, our group of 15 patients whose 
preoperative platelet count did not reach 40,000/cc was 
more likely to relapse after splenectomy (Table I), and 
the type of relapse was more likely to be severe and 
persistent, as clinically defined (Table II). 
After splenectomy, only two patients did not have an 
increased platelet count, and three patients could not be 
removed f rom steroid medication because of persistent 
thrombocytopenia. There was no statistically significant 
TABLE I 
Response to Splenectomy 
Highest Preoperative 
Platelet Count Relapse 
Sustained 
Response Total 
<40,000 6 9 15 
>40,000 10 65 75 
Not evaluable 3 5 8 
Total 19 79 98 
Chi-square = 6.081; Significance =0.0137 
Fisher Exact Probabil i ty = 0.0236 
TABLE 11 
Response to Splenectomy 
Clinical Relapse 
Highest Preoperative Clinical 
Platelet Count C roup 1 Group II Group i i l Response Total 
<40,000 3 2 1 9 15 
>40,000 6 1 3 65 75 
Not evaluable 1 0 2 5 8 
Total 10 3 6 79 98 
Chi-square =8,4811; 5 ignificance = 0.0370 
difference in the maximum platelet count reached after 
splenectomy between those patients who subsequently 
relapsed and those who did not. However, in those 
patients who sustained a good clinical response to sple-
nectomy, the platelet count reached its maximum level 
earlier than in those patients who relapsed (mean of 7.6 
days versus mean of 9.5 days) (Fig. 3). Those patients 
whose maximum platelet count occurred later after 
splenectomy (P=0.0003 at15 days) had a particularly high 
risk of relapse. 
Postoperative complications 
Of 98 patients, 23 developed 39 major postoperative 
complications. The 11 wound complications included 
evisceration (one patient), incisional hernia (two), and 
major wound infections (eight). The major pulmonary 
complications of six patients included labor consolida-
t ion and persistent infi l tration with fever. No patient had 
a pulmonary embolus, and o f the two patients who had a 
deep venous thrombosis, one also had an episode of 
deep venous thrombosis in the same leg years before 
chronic ITP had been diagnosed. In addit ion to 11 other 
major complications, there were four patients with a 
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Day of peak platelet count after splenectomy. 
subphrenic abscess, two with cardiac difficulties, two 
with pancreatitis, and one with chronic hepatitis. 
Those patients who developed major postoperative 
complications were older (Table 111), had larger spleens 
(Fig. 4), and experienced platelet counts that reached 
maximum levels later after splenectomy. This difference 
in the maximum level was more significant earlier in the 
postoperative period (P=0.0058 at 8 days versus P=0.0432 
at 11 days). 
Operative mortality and morbidity 
Three patients died early in the postoperative period 
from complications not specifically related to thrombo-
cytopenia. Al l three had responded well to splenectomy 
as determined by a good platelet response postopera-
tively. Ten patients died between seven months and 17 
years after splenectomy. Five experienced no recur-
rence of thrombocytopenia, and of the five who re-
lapsed, thrombocytopenia was a contr ibut ing factor in 
the death of only one. 
Discussion 
Of t h e l i variables we measured with respect to postop-
erative morbidi ty, platelet response, and nature of 
Age 
TABLE l l i 
Ma jo r Postoperative Complicat ions 
Number of 
Patients Percent 
<40 6/52 11.5% 
>39 17/46 37% 
Total 23/98 23.5% 
Chi-square = 8.7798; Si^ nif icance = 0.0001 
Fisher Exact Probability = 0.0030 
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Ma jo r postoperative compl icat ions related to spleen weight in 98 
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relapse, there was a correlation between postoperative 
morbidity and increasing age, larger spleen weight, and 
delay in reaching maximum platelet counts. There was 
no correlation among any of the other variables. 
Our study conf irmed previous reports which indicate 
that splenectomy gives good results for the treatment of 
chronic ITP (2-8). Furthermore, we found that long-
range patient fo l low-up is essential to provide accurate 
data, as the response to splenectomy may be delayed or 
incomplete, and an occasional late relapse occurred. 
Our study also emphasized that it was possible to 
achieve satisfactory preoperative platelet counts for 
nearly all patients with chronic ITP, if sufficiently large 
doses of steroids were administered. We recommend 
that after the decision has been made to perform sple-
nectomy, it should be carried out as soon as feasible. The 
patient should be given large doses of steroids, and once 
the platelet count reaches 40,000/cc or higher, any 
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further delays should be avoided. In general, we believe 
that platelet transfusions are not useful in preparing 
patients with ITP for splenectomy, since, even if the 
patient has received a large dose of steroids, donor plate-
lets are rapidly consumed in the recipient wi th chronic 
ITP. Preoperative plasmapheresis is a new technique that 
has been developed since this series concluded (9). 
Many authors have suggested that the patient's initial 
preoperative response to steroids wil l determine the 
effectiveness of splenectomy as treatment for chronic 
ITP (1,3,6,8,10-13). Although uniform criteria for response 
to steroids do not exist, and comparisons among differ-
ent series are thus not practical, our study did not con-
f i rm this reported relationship. Whi le 15 patients in our 
series had a poor clinical response to steroids as mani-
fested by a maximum preoperative platelet count of less 
than 40,000/cc, nine of them had a good response to 
splenectomy. Nevertheless, these 15 patients, who were 
receiving large doses of steroids, appeared at higher risk 
for relapse after splenectomy. 
Similarly, previous reports have indicated that the longer 
the duration of the disease, the poorer the patient's 
response to splenectomy, to steroids, or to other immu-
nosuppressive therapy (6,13,14). In our series, the dura-
t ion of the disease, as def ined by the duration either of 
symptoms or of known thrombocytopenia, did not 
correlate with the response or relapse after splenectomy. 
The pattern of the relapse correlated with the highest 
preoperative platelet count induced by steroid therapy, 
with the lowest preoperative platelet count, and with 
the day of the maximum platelet count postoperatively, 
but wi th none of the other variables. Others have 
reported that in those patients with chronic ITP who did 
not respond well to splenectomy or who relapsed after 
an initial good response, the maximum platelet count 
was delayed (10,13,15); our study confirmed this obser-
vation. However, in our patients the magnitude of the 
maximum postoperative platelet count was not predic-
tive of response or relapse. Also, whi le others have 
noted that those patients who had high platelet counts 
before splenectomy have a greater chance of a subse-
quent good response to splenectomy (12), this was not 
true in our series. 
In our patients who had significant postoperative com-
plications, the maximum peak in the postoperative plate-
let count was reached later, but this may reflect only the 
tendency of most acute illnesses to lower an individual's 
platelet count. It is noteworthy, however, that both 
patients with as well as those wi thout postoperative 
complications reached the same maximum platelet 
counts after splenectomy. 
The additional morbidity associated with larger spleens 
was surprising, as the largest spleen in our study (482 
gms) and in the other ITP series is still much smaller than 
the spleen sizes reported in the literature on the morbid-
ity of splenectomy for splenomegaly (16). 
While mortality is low in splenectomy series, morbidity 
has been commented on only casually in other reports 
(3,5,7,11). The increased morbidity in older age groups, 
we feel, reflects the surgical procedure rather than the 
underlying disease process, as the significant morbidity 
is not unusually high fo r the same procedure in younger 
age groups. 
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